Drug intelligence / Profile preview

IBT-001

Development stage: Preclinical
Lead developer: Interius Biotherapeutics
Modality: Small Molecules
Administration: Oral

Overview

IBT-001 is a preclinical, first-in-class, oral small molecule inhibitor of the NLRP3 inflammasome. Originally developed by Interius Biotherapeutics, it was acquired by Gilead Sciences to expand their inflammation portfolio. It is being investigated for the treatment of a variety of inflammatory diseases.

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on IBT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBT-001.

Explore the full profile